07 July 2016

Efforts will assist one of the most ambitious medical research programs in history of American medicine

Company continues digital health leadership through patient engagement and participation in PMI Cohort Program via Walgreens digital health platforms and Healthcare Clinics

DEERFIELD, Ill., July 07, 2016 - Walgreens will participate in the U.S. Precision Medicine Initiative (PMI) Cohort Program through an initial $20 million grant awarded to The Scripps Research Institute (TSRI) by the National Institutes of Health (NIH). The company will help support patient enrollment and participation in the program through its daily interactions with more than 8 million customers in stores, online and through its mobile app. The award will total almost $120 million over five years and is part of President Obama’s Precision Medicine Initiative, one of the most ambitious medical research programs in the history of American medicine aimed at revolutionizing how researchers, providers and research participants work together to develop individualized care.

“As a trusted health care resource to the millions of customers and patients we see every day, Walgreens will help launch this important program that can lead to delivering the right treatments at the right time to help Americans live longer, happier and healthier lives,” said Co-Chief Operating Officer of Walgreens Boots Alliance Alex Gourlay.

With this funding award, Walgreens will offer customers enrollment in the PMI Cohort Program at its stores, at Walgreens Healthcare Clinics, online through Walgreens.com and through the Walgreens mobile app. For those who enroll, Walgreens also can schedule their initial appointment for the program.

“Walgreens has a long commitment to implementing innovative digital tools to improve the health and wellbeing of our customers we serve every day across the country,” said Brad Fluegel, Walgreens senior vice president, chief healthcare commercial market development officer. “Our participation in the Precision Medicine Initiative Cohort Program will help shape the future of pharmacy by developing more precise medications, based on a person’s genetic and other biological information and lifestyle, that can reduce side effects and drug interactions while increasing their effectiveness.”

The PMI Cohort Program is a landmark longitudinal research effort that aims to engage 1 million or more U.S. participants to improve the ability of preventing and treating disease based on individual differences in lifestyle, environment and genetics. Participants will share their health history and status, genomic and other biological information, and grant access to their clinical data from electronic health records. In addition, mobile health devices and apps will provide lifestyle data and environmental exposures in real time. The knowledge gained from the program is expected to extend successes of precision medicine in some cancers to many other diseases and also increase an individual’s chances of remaining healthy throughout life.

About Walgreens

Walgreens (www.walgreens.com), one of the nation's largest drugstore chains, is included in the Retail Pharmacy USA Division of Walgreens Boots Alliance, Inc. (NASDAQ: WBA), the first global pharmacy-led, health and wellbeing enterprise. More than 8 million customers interact with Walgreens each day in communities across America, using the most convenient, multichannel access to consumer goods and services and trusted, cost-effective pharmacy, health and wellness services and advice. Walgreens operates 8,173 drugstores with a presence in all 50 states, the District of Columbia, Puerto Rico and the U.S. Virgin Islands. Walgreens digital business includes Walgreens.com, drugstore.com, Beauty.com and VisionDirect.com. More than 400 Walgreens stores offer Healthcare Clinic or other provider retail clinic services.


Alyssa Bronikowski
(847) 315-8144